What Do the Trials Say for Catheter Ablation?-VT Ablation — What Do the Trial Say (Presenter: John L. Sapp, MD, FHRS)

VT Ablation — What Do the Trial Say (Presenter: John L. Sapp, MD, FHRS)

Video Transcription

Video Summary

Dr. John Zapp gives an overview of the trials conducted on ventricular tachycardia (VT) ablation. He starts by highlighting the challenges of conducting clinical trials in this area and the limited number of trials available. However, he emphasizes that VT ablation does work and is better than alternative treatments. He discusses several of the completed randomized clinical trials, including SMASH VT, VTAC, SMS, and VANISH. He explains their findings and highlights the importance of on-treatment analysis in assessing the effectiveness of VT ablation. He also discusses sub-studies that looked at different factors such as drug therapy, cost-effectiveness, quality of life, and induction testing. Dr. Zapp briefly mentions upcoming trials that will further explore the role of VT ablation as first-line therapy and the timing of intervention. He concludes by emphasizing the need for further research on VT ablation and its outcomes.

Meta Tag

Lecture ID 5219

Location Room 303

Presenter John L. Sapp, MD, FHRS

Role Invited Speaker

Session Date and Time May 10, 2019 10:30 AM - 12:00 PM

Session Number S-058

Keywords

Ventricular tachycardia ablation

Clinical trials

On-treatment analysis

First-line therapy

Research outcomes